Key words
intracerebral hemorrhage - anticoagulation - hematoma enlargement - blood pressure
reductions - reversal
Epidemiology & Etiology
One of the most serious forms of stroke is intracerebral hemorrhage (ICH) as fewer
than 30% of patients recover to functional independence and the one-year mortality
rate of over 50% is very high [1]
[2]
[3]. In hemorrhagic stroke, oral anticoagulation-associated intracerebral hemorrhage
(OAC-ICH) is of particular concern because it is associated with larger hemorrhage
volumes, increased ventricular extensions, and more frequent and protracted hematoma
enlargement [4]
[5]
[6]
[7]. All of these parameters are validated for a negative prognosis, which is even poorer
considering the patient characteristics that necessitated oral anticoagulation in
the first place [1]
[8]
[9]
[10]. These patient characteristics usually include advanced age and a pronounced cerebrovascular
risk profile and are also associated with a high risk of hemorrhage and thromboembolism
[1]
[8]
[9]
[10]
[11]. Currently the European and international guidelines offer very few evidence-based
treatment recommendations for these critically ill patients [1]
[8]
[12]
[13].
In Germany, the incidence of hemorrhagic stroke is currently about 50 per 100 000
patient-years and falling (between 1990 and 2010), and the mortality rate has dropped
by nearly half in this time period [14]. Of the total number of ICHs, approximately 15–25% is related to oral anticoagulation
[10]
[15]
[16]. The incidence of OAC-ICH is therefore approximately 10 per 100 000 patient-years
in Europe, and anticoagulants increase the risk of hemorrhage almost tenfold [7]
[17]. Epidemiological studies indicate that the incidence of ICHs in the western hemisphere
has been relatively stable or has fallen over the last several decades. In contrast,
OAC-ICHs and the atypical ICHs discussed below are of special significance because
the incidence of these hemorrhage entities is expected to increase [2]
[14]
[18]. Due to their localization, intracerebral hemorrhages are generally categorized
as typical or atypical and presumed to have differing pathoetiogeneses. The typical
(or “loco typico”) ICH is limited to the basal ganglia region, in some cases with
involvement of the thalamus. The primary genesis of this form of hemorrhage is hypertension,
because the resulting vascular damage causes the striatal vessels to rupture. An atypical
hemorrhage is lobar and characterized by the involvement of cortical and subcortical
structures [2]. This form of ICH has particular characteristics and is often associated with cerebral
amyloid angiopathy (CAA), which in itself is characterized by multiple microbleeds
and more frequently recurring macrobleeds [2]
[19]
[20]. This vulnerability to hemorrhage may represent a relevant association or even a
theoretical predisposition for the occurrence of an oral anticoagulant-associated
ICH. The increase in atypical ICHs could therefore be associated with the increasing
incidence of atrial fibrillation and the resulting more frequent use of anticoagulants
alongside the demographic change [2]
[18]
[20]
[21].
For patients aged 65 and older, the incidence rate of an ICH without oral anticoagulation
is the lowest, at approximately 0.3% per year [14]. In the global context, high-income countries should be differentiated from low-
and middle-income countries, because the ICH incidence rate in the latter is more
than twice as high and significantly increasing [14]. For patients under oral anticoagulant therapy, the most relevant difference is
the form of oral anticoagulation. For patients taking vitamin K antagonists (VKA),
the annual incidence rate is approximately 1% compared to patients taking novel oral
anticoagulants (NOAC) whose incidence was half that [22]. It should be noted, that the data used was evaluated within the framework of the
major NOAC clinical trials (n=10 000) and reflects a selected patient cohort. “True”
clinical data suggests that the incidence of OAC-ICH in patients who have never suffered
an intracranial bleed is probably somewhat higher – approximately 1–2% [23]. The presumed largest relative increase in the incidence rate is evident in patients
who have already suffered an ICH and are treated with anticoagulants due to the high
risk of thromboembolism. For this patient cohort, the weight of evidence is not optimal,
although possible incidence rates of up to 10% per year are assumed [10]
[15]
[24]
[25]
[26]
[27]
[28].
Risk Factors for an OAC-ICH
Risk Factors for an OAC-ICH
Due to similar risk factors, the risk for hemorrhagic complications rises basically
in parallel with the risk of thromboembolism. Validated ischemic risk scores (CHADS2,
CHA2DS2-VASc) provide a way to assess the risk of hemorrhage. Hemorrhage-specific
scores (HAS-Bled, HEMORR2HAGES) that account for conventional risk factors, liver
and kidney function problems, and taking anticoagulant medications allow for a more
precise estimate of hemorrhage risk [9]
[11]
[29]
[30]. For patients taking VKA anticoagulants, a correlation was demonstrated between
the degree of anticoagulation, as measured by the INR, and the probability of occurrence
of a hemorrhagic stroke. In the supratherapeutic INR range, the risk of hemorrhage
rises dramatically, i. e., more than fivefold at an INR between 4 and 4.5 and nearly
twentyfold at an INR greater than 4.5. For patients taking NOACs, a similar correlation,
e. g., between the plasma concentration of the given preparation and the probability
of occurrence of an ICH, could not yet be demonstrated [31]. However, this could be due to the lack of internationally uniform and standardized
level-measurement procedures and the relatively short time these medications have
been in daily clinical use. The patient’s age is a major factor associated with the
occurrence of extra- and intracranial bleeds in patients under oral anticoagulant
therapy. Starting at the age of 35, the patient’s risk of the incidence of ICH doubles
every ten years [32]. Explicitly for patients under oral anticoagulant therapy, a post-hoc analysis of
the ROCKET-AF data showed an independently significant association between patient
age (increase of 10 years) and the occurrence of an intracranial hemorrhage (hazard
ratio: 1.35 (1.13–1.63), p=0.001) [33]. Similarly, data from the RE-LY trial also showed an independent association between
patient age (age>75 years) and serious bleeding complications [34]. In a prospective study of just under 500 patients recently started on oral anticoagulation
with vitamin K antagonists, there was also an age-dependent difference in the bleeding
incidence over the course of 1 year (age≥80 years: 13.1 versus age<80 years: 4.7;
per 100 person-years p=0.009) [23].
Not only oral anticoagulation alone, but additive medications influencing coagulation
may even further increase the risk of recurrent hemorrhage. Dual therapy with antiplatelet
drugs and oral anticoagulation is of particular concern in this regard. Available
data from Germany indicates that, at least in patients who have suffered an OAC-ICH,
approximately 11% were taking platelet function inhibitors at the same time [10]. Randomized data showed that the bleeding incidence from added antiplatelet drugs
at least doubled the intracranial bleed complication rate with simultaneous oral anticoagulation
[35]. There have been no studies to date examining such dual therapy in patients who
have suffered a cerebral hemorrhage. Yet a leading medical journal reported on a study
of over 1 000 ICH patients, and albeit the main purpose was to evaluate the influence
of long-term blood-pressure control after ICH, there do appear to be independent effects
of platelet function inhibition on ICH recurrence [27]. In this study, Biffi et al. clearly demonstrated this independent association after
lobar ICH in that the risk of recurrent hemorrhage under platelet inhibitor therapy
was nearly three times higher (hazard ratio 2.89 (1.32–6.30); p=0.008). For patients
with non-lobar ICH, this unfavorable influence was less pronounced (hazard ratio 1.56
(0.98–2.48); p=0.06). For both hemorrhage entities, the most important result of this
study was the consistent and independent influence of poorly adjusted antihypertension
therapy with rebleeding rates (blood pressure: systolic>140 mmHg, diastolic>90 mmHg)
in the long-term course post-ICH. Not only could the independent influence of poorly
controlled hypertension on the recurrent hemorrhage rate be established, but there
was also a correlation between blood pressure adjustment and bleeding risk, i. e.,
the higher the systolic blood pressure (in 10 mmHg intervals), the higher the probability
of occurrence of another ICH.
Another factor that is related to the increased occurrence of ICH is cerebral amyloid
angiopathy (CAA). This disease is characterized by excess deposits of beta-amyloid
in the small and medium-sized blood vessels in the cortical and subcortical regions
as well as the leptomeningeal vessels. Histologic examination is required for definitive
diagnosis, however further imaging tests (MR: T2, SWI, GRE sequences) can be used
to diagnose a probable CAA [36]. In CAA, the white matter, the deep gray matter and the brain stem are generally
spared from microbleeds. Microbleeds can also be present in deep ICH, but then are
restricted to the basal ganglia associated with a hypertensive vasculopathy. The morphological
imaging correlates of CAA are multiple microbleeds in the lobar localization particularly
in the temporal and occipital lobes versus the frontal and parietal lobes [19]
[36]. Like Alzheimer’s disease, the incidence of CAA appears to be correlated with age
and there are clear associations between CAA and the increased occurrence of ICH and
recurrent hemorrhage [37]. After age, anticoagulant medications appear to have a stronger influence, because
an accumulation of microbleeds is found in ICH-naïve patients not only under anticoagulation,
but also under antiplatelet drug therapy [38]
[39]. Likewise, a comparison of the microbleed burden in patients who have suffered an
ICH with and without anticoagulation showed a marked accumulation of microbleeds under
antiplatelet and oral anticoagulation therapy [38]
[39]. Furthermore, CAA exhibits a genetic association with ApoE (epsilon 2 & 4) alleles
and is associated with a higher risk of re-bleeding in carriers of these alleles [40]. In an overall view of the ICH risk factors described, patients with lobar hemorrhage
have a higher risk of recurrence (3.4% versus 7.8% per year) than those with basal
ganglia bleeds because they are usually older, have more frequent microbleeds and
CAA, as well as increased comorbidities with a simultaneous indication for anticoagulant
medications [27]
[38]
[39].
Assessment of Prognosis and Specific Characteristics of OAC-ICH
Assessment of Prognosis and Specific Characteristics of OAC-ICH
Compared to OAC-ICH, the validated prognostic parameters of primary ICH are identical,
although there are specific differences in possible therapeutic approaches to acute
treatment, which will be described in the following. Generally, all validated predictors
of OAC-ICH are more pronounced, leading to a poorer functional condition and a higher
mortality rate after OAC-ICH. The validated prognostic parameters are: age, neurological
status (GCS, NIHSS), hematoma volume, ICH localization, intraventricular hemorrhage,
and hematoma progression.
As already discussed, patient age is a critical prognostic parameter in stroke patients
and also significantly influences the functional condition of those who survive ICH.
Accordingly, age is a component in all commonly used risk scores (e. g., ICH score,
FUNC score) to prognosticate mortality and functional outcome [41]
[42]
[43]. In a prospective study, the influence and significance of the Glasgow Coma Scale
(GCS) was investigated as a substitute for neurologic status in over 1 000 ICH patients
to predict 30-day mortality [44]. Compared to the ICH score, the categorized GCS was similarly predictive (ICH score:
area under the curve=0.861 versus GCS: area under the curve=0.872) [44]. The National Institutes of Health Stroke Scale (NIHSS) is the most important quantitative
measurement of neurologic status after stroke and is explicitly stressed in the current
American guidelines for ICH treatment [1]. In large stroke registry studies (n>10 000) including ICH patients, the strength
and relevance of the NIHSS to predict prognosis was demonstrated, and the NIHSS also
improved the predictive value of previous scores for ICH patients [45].
The most important prognostic parameter is the initial hematoma volume, and a volume
greater or less than 30 ml is a very frequently used threshold to assess prognosis
and define inclusion criteria in randomized studies [1]
[46]
[47]. Hematoma localization also plays an important role. In supratentorial bleeds, the
lobar ICH appears to be associated with a generally better outcome than basal ganglia
bleeds, whereas infratentorial ICHs are associated with a poorer prognosis. Basal
ganglia bleeds are accompanied significantly more often by intraventricular hemorrhage,
which may lead to occlusion of the 3rd and 4th ventricle associated with an acute
hydrocephalus, a consecutive rise in brain pressure and – in the worst case – herniation.
Various studies have shown that not only does the presence of intraventricular hemorrhage
worsen prognosis but so does the ventricular blood volume [4].
The hematoma progression is the most clinically relevant prognostic parameter because
it seems to be generally treatable. It is important to differentiate between treatable
and nonmodifiable parameters; patient age, initial hematoma volume, and neurologic
status are not modifiable, whereas hematoma growth and intraventricular extensions
are events that arise especially in the acute phase (0–72 h) and are amenable to treatment.
These treatable parameters – hematoma growth and ventricular intrusion – play a special
role particularly in the acute treatment of OAC-ICHs, because they occur much more
frequently than in primary ICHs and represent an extremely relevant therapeutic target.
The literature on OAC-ICHs describes not only a cumulative but also a prolonged occurrence
of hematoma progression; furthermore, hematoma growth seems to be accompanied by repeat
ventricular intrusion [4]
[5]
[6]. Additionally, intraventricular hemorrhage in OAC-ICH appears more frequently and
is especially more pronounced. In summary, this treatment goal – avoiding hematoma
growth and recurrent intraventricular hemorrhage– in OAC-ICHs represents a potentially
very relevant treatment target in acute –ICH care that may be able to influence functional
endpoints through targeted interventions.
Based on a post-hoc analysis of the randomized INTERACT 1 & 2 studies, described in
greater detail in the following, a prognosis model (BRAIN score) was developed to
assess the risk of hematoma growth [48]. The model has a maximum point value of 24, at which the probability of occurrence
of hematoma growth was determined to be 86% with overall good discrimination (c-statistic,
0.73). The following influencing parameters – ICH volume, previous ICH, intraventricular
hemorrhage, anticoagulation, and time window (onset of symptoms to diagnosis) – were
identified and built into the model. Along with hematoma volume, the highest weighted
parameters were existing anticoagulation (6 points) and time window (<1 h=5 points)
[48]. This illustrates the relevance of the time window not only in ischemic but also
hemorrhagic stroke patients. On this basis, patients with a high risk for a prognosis-relevant
complication may be able to be identified and treated early on. The time window –
not only onset of symptoms to diagnosis but also diagnosis until start of antagonization
and acute therapy – plays a major role especially in OAC-ICHs, because the treating
physician can positively influence the parameters that are independently associated
with hemorrhage progression [10].
Acute Treatment Within the First 24 h
Acute Treatment Within the First 24 h
The main goal of acute treatment of OAC-ICH is to minimize the risk of hematoma expansion
to prevent further secondary worsening due to ICH volume effects and intracranial
pressure elevations ventricular intrusion with acute hydrocephalus, and finally herniation.
As already discussed, complications from hematoma growth in OAC-ICHs are significantly
more frequent than in spontaneous ICHs and can occur protractedly for up to 72 h after
the initial event [6]
[49]. Current studies suggest that hematoma growth occurs in well over one-third of patients
with OAC-ICH, whereby differences in the risk of hematoma growth between VKA- and
NOAC-associated hemorrhaging remains unclear [10]
[50]. To avoid hematoma expansion, current guidelines recommend working toward rapid
normalization of coagulation and effective lowering of blood pressure in the acute
phase [1]. However, the guidelines do not yet include the target values cited in the current
data for rapid normalization of coagulation of VKA-ICH (the specific time window and
INR value).
Lowering blood pressure
There are currently multiple randomized studies that have investigated the significance
of aggressively lowering blood pressure on outcome and hematoma progression in spontaneous
ICHs. In the randomized INTERACT 1 pilot study [51] published in 2008, the effect of an intensive reduction in blood pressure (systolic
target value 140 mmHg) versus the then recommendation in the guidelines (target value
180 mmHg) on hematoma expansion was investigated in 404 patients. A more aggressive
reduction in blood pressure was associated with a lower proportional hematoma growth
after 24 h (intervention group: 13.7% versus control group: 36.3%; p=0.04) and the
risk of hematoma growth (defined as >33%) was 36% lower compared to the control group
(p=0.05). No differences were noted with respect to undesirable side effects or complications
[51]. The multicenter ATACH 1 trial investigated the influence of blood pressure reduction
using nicardipine (to one of three target ranges: systolic blood pressure 110–139 mmHg/140–169 mmHg/170–199 mmHg)
on the rate of hematoma expansion and the extent of perihemorrhagic edema, and functional
outcome after three months [52]. Although no clinical benefit was demonstrated, the trial was not designed to detect
differences in efficacy but to prove the safety of the above-cited therapy concepts.
The ICH-ADAPT study [53] was able to allay initial safety concerns that aggressive intravenous blood pressure
reduction could reduce cerebral blood flow in the perihemorrhagic penumbra and promote
secondary neurological damage. The INTERACT 2 trial published in 2013 in the New England
Journal of Medicine compared rapid blood-pressure lowering (target systolic value<140 mmHg)
with a moderate reduction (target value<180 mmHg) in 2 839 ICH patients within six
hours after onset of hemorrhage. The treating physician was responsible for selecting
the antihypertensive medication administered. In nearly 90% of patients in the intervention
group (compared to 43% in the control group), the administration of i. v. antihypertensives
was necessary to achieve the target blood pressure values. The medication most frequently
given was urapidil (32.5%), followed by calcium-channel blockers (16.2%). The primary
endpoint (poor outcome defined as modified Rankin score of 3–6 after 90 days) was
just missed (OR 0.87 for rapid blood-pressure lowering (95% CI: 0.75–1.01); p=0.06),
although an ordinal shift analysis of outcome and quality of life suggests that rapid
blood-pressure lowering is of benefit after three months [54]. The subanalysis of 964 of the study participants who underwent brain imaging after
24 h showed an effective minimization of hematoma growth, especially in those patients
treated earlier and more aggressively. However, it should be noted that only approximately
one third of the patients in the intensive-treatment group actually achieved the target
blood pressure of <140 mmHg [54]. Also recently published in the New England Journal of Medicine, the ATACH 2 trial
attempted to achieve the clinical endpoint through earlier, aggressive blood pressure
reduction because of the increased risk of hematoma expansion in the early phase of
ICH [55]. The target values (110–139 mmHg vs. 140–179 mmHg) were to be achieved within 4.5 h
after onset of symptoms through intravenous administration of nicardipine. After the
interim analysis produced negative results, the trial was discontinued prematurely
at 1 000 patients before reaching the target enrollment of 1 280 [55]. Intensive blood-pressure lowering proved no more effective than the standard treatment
(modified Rankin score 4–6 after three months: intensive blood-pressure lowering 38.7
vs. 37.7%; RR 1.04 (0.85–1.27)) and was associated with a greater number of serious
adverse events – especially an increase in renal complications – during the three-month
observation period (serious complications: intensive-treatment group 25.6 vs. 20.0%
in the standard-treatment group; relative risk 1.30 (95% CI, 1.00–1.69); p=0.05).
Nonetheless, a statistical advantage in support of a reduced rate of hematoma expansion
was also observed in this trial for the intervention group (standard treatment 24.4
vs. 18.9% in intensive-treatment group; RR 0.78 (0.58–1.03); p=0.08). Compared to
INTERACT 2, all patients in the ATACH 2 trial were treated earlier and more aggressively,
so in fact the blood pressure values in the control group were at the level of the
patients who received intensive blood-pressure lowering treatment in the INTERACT
2 trial. At systolic values less than 130 mmHg – like those achieved in the treatment
group in ATACH 2 (mean value 128 mmHg in the treatment arm) – it is possible that
the side effects outweigh the positive effects on hematoma expansion. Caution is advised
with respect to comparability and applying study results to German clinical practice
and OAC-ICH. Unlike in the INTERACT 2 trial, the ATACH 2 trial excluded patients with
OAC-ICH (INR≥1.5) and the antihypertensive was restricted to nicardipine – a calcium-channel
blocker that is not approved for use in Germany, and due to its strong vasodilatory
effect, is associated with cardiovascular and CNS side effects (including increased
intracranial pressure) [55]
[56].
Currently, the German-wide multicenter observational study RETRACE offers the most
valid data basis for the value of blood pressure management in OAC-ICH; the study
investigated both acute management as well as resumption of OAC after hemorrhage under
treatment with marcumar [10]. The study conducted at 19 neurovascular centers included 1 176 patients with marcumar-ICH
defined as INR>1.5 on admission; 853 patients were available for analysis of hematoma
expansion via brain imaging. Blood pressure values were recorded at 4-h intervals
over the first 24 h after admission and tiered analysis performed in 20 mmHg intervals.
In the adjusted multivariate analysis, a systolic blood pressure of <160 mmHg within
4 h after admission was associated with a significantly reduced rate of hematoma expansion
(33.1% vs≥160 mmHg 52.4%; p<0.001). To date, there have been no NOAC-ICH study results
published that analyzed the value of blood pressure reduction. Finally, as-yet unpublished
data for just under 200 NOAC-ICH patients in connection with a multicenter follow-up
project of the German RETRACE trial (over 2 500 OAC-ICH patients) indicate a similar
relationship between blood pressure reduction and reduced hematoma expansion (Gerner
et al., in revision). As a whole, the current data suggests that aggressive and early
hemorrhage management (systolic blood pressure target of 140 mmHG as quickly as possible,
but at least within 4–6 h), even in patients with altered coagulation, is a safe and
effective way to prevent hematoma expansion, whereby a forced blood pressure reduction
lower than the above-mentioned target values should be avoided.
-
The goal of minimizing the risk of hematoma expansion is aggressive intravenous reduction
of systolic blood pressure targeting 140 mmHg.
-
As quickly as possible!
-
However, hypotonic values (mean arterial pressure less than 80 mmHG) should be avoided
in order to maintain cerebral perfusion should there be any intracranial hypertension.
Antagonization VKA-ICH
Normalizing coagulation is the crucial starting point in acute treatment of OAC-ICH.
Prior to anticoagulant reversal, however, the given substance should be checked for
effective administration ([Table 1]). In VKA-ICH, anticoagulant reversal can be achieved by administering coagulation
factors – such as fresh frozen plasma (FFP) or coagulation concentrates (PCC, prothrombin
complex concentrates) – as well as providing vitamin K. In a randomized, plasma-controlled,
phase IIIb trial, the coagulation of 202 patients with vitamin-K antagonist-associated
hemorrhage, of whom only 24 had an intracranial bleed, was corrected more quickly
with a combination of vitamin K and PCC than with FFP (INR≤1.3 30 min after end of
infusion: PCC+vitamin K 62.2% vs. 9.6% FFP+vitamin K) [57]. In another phase III study, vitamin-K antagonist patients (n=181) with an INR≥2.0
and acute indication for surgical intervention were randomized and treated either
with PCC (INR 2–4: 25 IU/kg KG; INR 4–6: 35 IU/kg; INR>6: 50 IU/kg) or FFP (INR 2–4:
10 ml/kg; INR 4–6: 12 ml/kg; INR>6: 15 m/kg), each in combination with vitamin K [58]. In the PCC group, the surgical intervention could begin sooner after infusion started
(PCC: 3.6 (1.9–10.8) h vs. 8.5(2.8–18.7) h in the FFP group; p=0.0098) and more frequently
with coagulation normalized (PCC 90% vs. FFP 75%).
Table 1 Reversal management in oral anticoagulation associated ICH.
|
VKA
|
NOAC
|
|
Dabigatran
|
Factor Xa inhibitors
|
|
Indication
|
INR≥1.3
|
Ingestion<3–5 terminal* half-life times or Hemoclot>30 ng/ml (*no renal insufficiency)
|
Ingestion<3–5 terminal half-life times or calibrated anti-XA level>30 ng/ml
|
|
Acute treatment
|
PCC
[57]
INR 2–3.9–25 IU/kg
INR 4.0–6.0–35 IU/kg
INR>6.0–50 IU/kg
If needed, re-administer after INR check<4 h simultaneous i. v. vitamin K (10 mg)
|
Idarucizumab
If available
Otherwise PCC
50 IU/kg
Active charcoal (within 4 h) if needed
|
PCC/FEIBA
50 IU/kg
Active charcoal (within 4 h) if needed
|
* These values vary depending on kidney function and drug interactions. Please review
product characteristics in each case
The only randomized, controlled study (INCH) published to date investigated the hemostatic
potency of the different preparations in patients with VKA-ICH [59]. Fifty-four patients with VKA-ICH (INR≥2 on admission; inclusion within 12 h after
onset of symptoms) were randomized and treated either with PCC (30 IU/kg; n=27) or
FFP (20 ml/kg; n=23) combined with vitamin K (10 mg i. v.). In addition to the normalization
of coagulation (INR≤1.2 within 3 h after start of treatment), the study also included
clinical endpoints such as rate of hematoma expansion and functional outcome at 90
days. The trial was terminated after inclusion of 50 of the 74 initially planned patients
due to safety concerns in the FFP treatment group. PCC effectively normalized coagulation
far more frequently (INR≤1.2 within 3 h: PCC 67% vs. FFP 9%; OR 30.6 (4.7–197.9);
p=0.0003). After 24 h, the patients in the FFP treatment group evidenced greater hematoma
expansion (ICH volume difference 16.4 mL, (95% CI: 2.9–29.9; p=0.018) and were at
four times greater risk of hematoma expansion defined as a >33% increase in volume
over the initial volume, or death. The rate of thromboembolic complications was comparable
for both substances [59]. Considering volume strain, possible allergic reactions, and the need for AB0-compatible
transfusion of fresh plasma, according to current data PCC should be preferred to
normalize INR levels as quickly as possible [1].
Furthermore, there are current results of two major multicenter cohort studies on
the topic of antagonization in the acute phase. A retrospective, pooled analysis of
over 1 500 VKA-ICH patients from 19 countries addressed the question of which agents
can normalize INR most effectively [60]. The lowest rate of hematoma expansion, from lowest to highest, was achieved with
a combination of PCC and FFP, PCC alone, and FFP alone (hazard ratio for hematoma
expansion: 27.8% (reference), 37.3%, 45.6%). Due to the retrospective design of this
study, however, interpreting the study results for clinical application is critical,
it may be more likely that the combined FFP+PCC approach could be viewed as an indicator
for aggressive therapy in this treatment group. The previously mentioned German retrospective
cohort study (RETRACE) of VKA-ICH patients was devoted to the question of which INR
value should be targeted within which time window in order to minimize the rate of
hematoma expansion. The rate of hematoma enlargement was significantly reduced, regardless
of preparation administered (almost 90% with PCC alone or in combination), when the
INR value achieved after correction was <1.3 (INR<1.3: 26.9% versus INR≥1.3: 45.4%;
p<0.001) [10]. A more aggressive hemostatic treatment to INR values<1.2 was not associated with
any further drop in rate of hematoma expansion in this study. This positive effect
of hemostatic treatment could be demonstrated up to approximately 4 h after hospital
admission (INR<1.3 within 4 h: 22.4% versus 42.2%; p=0.02) and was even more pronounced
the earlier treatment was initiated and antagonization achieved (see [Fig. 1]). In the adjusted analysis, effective (control INR<1.3) and early (within 4 h after
admission to hospital) anticoagulant reversal combined with a systolic blood pressure
of <160 mmHG after 4 h was observed to reduce the hematoma expansion the most (OR
0.17 (95% CI: 0.11–0.33); p<0.001). Furthermore, in-hospital mortality of patients
who were treated based on those targets was significantly reduced. Due to the negative
results, safety concerns, and an increased rate of thromboembolic complications in
the FAST trial, which was a phase III study on the efficacy of recombinant activated
factor VII (rFVIIa) in ICH patients, the administration of rFVIIa is not recommended
at this time [1]
[61]. Existing studies produced neither proof of efficacy nor safety concerns for another
substance, the antifibrinolytic tranexamic acid, which is currently being investigated
in randomized trials (TICH: ISRCTN50867461 and STOP-AUST: NCT01702636 ). Due to its
delayed effect, vitamin K is not appropriate for immediate coagulant reversal, but
should be simultaneously replaced (10 mg i. v.) because otherwise INR can rise again
due to PCC’s extremely short half-life compared to conventional VKA [1]
[62]. After antagonization, INR checks should be conducted regularly and coagulation
factors replaced again if needed [1].
Fig. 1 Acute treatment of VKA-ICH (RETRACE study, n=853) [10].
-
The goal for minimizing the risk of hematoma growth is immediate intravenous antagonization
with PCC (see [Table 1] for dose) and vitamin K (10 mg i. v.) simultaneously.
-
Serial coagulation check should be obtained after reversal treatment.
-
Antagonization to an INR target value at least less than 1.3, 1.2 possibly better.
-
This target value (INR<1.3) should be achieved as fast as possible, at least 4 h.
Antagonization NOAC-ICH
Based on the relatively short elimination half-life of NOACs (dabigatran 12–17 h,
rivaroxaban 5–13 h, apixaban 12 h, edoxaban 10–14 h) in comparison to VKA (marcumar
72–96 h), pausing the corresponding NOAC preparation could theoretically suffice in
cases of NAOC-ICH, depending on the last ingestion and the concentration levels measured.
However, this approach should be weighed very carefully because ICH is the most serious
complication, mechanical hemostasis is impossible, and level measurement is unvalidated,
time-consuming, and not available everywhere. Accordingly, hemostatic treatment should
be immediately started for NOAC-ICHs as well.
Should anticoagulant reversal be necessary, either administering specific antidotes
or replacing coagulation factors can be considered. At least for dabigatran, an effective
and easy-to-administer antidote in the form of idarucizumab (Praxbind), a monoclonal
antibody fragment, has been clinically available since the beginning of 2016. A published
interim analysis and current conference data (Nov. 2016 American Heart Association
Scientific Sessions; n=494) of the recently completed prospective, single-arm, open-label
RE-VERSE AD study are available. The study demonstrated the safety and efficacy of
this antibody to reverse the effects of dabigatran in patients with serious bleeding
(Group A, n=285) or requiring an urgent surgical procedure (Group B, n=196) [63]. The primary endpoint of normalized coagulation test results (dilute thrombin time
and ecarin clotting time) was achieved in all patients within 4 h by administering
5 g of idarucizumab (two boluses of 2.5 g i. v.). Dilute thrombin time was reduced
within 10 to 30 min of administration and remained below the normal limit over 4 h
for both coagulation times. However, it should be mentioned that at least on the basis
of the data from the interim analysis, just under 25% of the patients had a normal
dilute thrombin time at the time of inclusion in the study and therefore exhibited
little or no effect of dabigatran. In patients requiring surgery, treating surgeons
reported normal hemostasis in 92% of cases [63]. Accelerated approval was issued in November 2015, making idarucizumab available
for daily clinical use in Germany to reverse the effects of dabigatran since the beginning
of this year. An initial case report on its use for intracerebral hemorrhages in patients
taking dabigatran appears promising; no hematoma expansion was observed in 2 patients
after idarucizumab was administered [64]. For patients taking factor Xa inhibitors, a clinical trial is currently underway
to investigate andexanet alfa, a recombinant factor Xa protein with no intrinsic catalytic
activity. The ANNEXA-4 study examined the extent to which the effect of factor Xa
inhibitors (rivaroxaban, apixaban, edoxaban and enoxaparin) could be reversed in patients
with acute major bleeding [65]. Over 67 patients received a bolus of andexanet followed by a 2-h continuous infusion.
After administration of the bolus, the median value for anti-factor Xa activity fell
by 89% in patients taking rivaroxaban and 93% in patients taking apixaban, and 39%
and 30% respectively four hours later. Twelve hours after the infusion, hemostasis
was re-evaluated and 79% of patients with initially elevated anti-factor Xa levels
(defined as >75 ng/ml) were assessed as good or better. For ICH patients, these results
should be critically evaluated due to the very conservative definition of good coagulation,
an increase in volume<35% in ICH patients, and the long time interval (12 h) between
the end of infusion and evaluation of efficacy, which is approximately equal to the
elimination half-life of antagonized NOAC derivates. An accelerated approval process
based on the submitted data was not authorized by the FDA in the US [66], so andexanet alfa is currently not approved for clinical application outside of
trials. Another antidote currently in development is ciraparantag (PER977), which
unlike the above-mentioned preparations, is intended to bind and eliminate factor
Xa inhibitors, dabigatran and heparin derivates through the formation of hydrogen
bonds. Initial animal experiments were not very promising and approval is not expected
any time soon [67].
Due to the lack of alternatives, the current European and international guidelines
for ICHs that occur under treatment with factor Xa inhibitors recommend administering
PCC or activated coagulation concentrates (FEIBA) at an initial dose of 50 IU/kg [68]. The recommendations are based mainly on experimental studies in which PCC was observed
to prolong prothrombin time in healthy subjects taking rivaroxaban [69] and edoxaban reduced bleeding duration [70]. In the German-wide RASUNOA register, in which ischemic and hemorrhagic stroke patients
under NOAC treatment were prospectively recorded, PCC was not observed to provide
any benefit for NOAC-associated ICHs (hematoma expansion: 12/28 with PCC (43%) versus
5/17 (29%) without PCC; p=0.53) [50]. In a small case study of NOAC-associated ICHs (n=5), no hematoma expansion occurred
after administration of activated coagulation concentrates (FEIBA), however FEIBA
infusion was begun within a median of 13 h (range 10–29 h) from the last NOAC dose,
so at this time effective anticoagulation was presumably no longer present depending
on the medication [71]. If NOAC was taken within 2–4 h of the hemorrhage, activated charcoal can be administered
to minimize the adsorption of the active substance [72]
[73].
-
The goal to minimize the risk of hemorrhage growth in the event of dabigatran-associated
ICH is immediate intravenous antagonization with 5 g idarucizumab.
-
The goal to minimize the risk of hemorrhage growth in the event of factor Xa inhibitor-associated
ICH should be immediate intravenous antagonization with at least 50 IU/kg PCC or FEIBA
(no evidence).
-
The administration of active charcoal may be considered if time of ingestion is known
to be early (within 4 h after onset of symptoms).
Acute Treatment Starting Day 2
Acute Treatment Starting Day 2
Patients with ICH should always be treated in specialized centers with a high annual
throughput. This recommendation concurs with the current guidelines and is based on
valid evidence. An American prospective study of ICH patients showed increased in-hospital
mortality when patients were treated in a general ICU compared with a specialized
neuro ICU (OR=3.4; CI 1.6–7.6), with high patient volume and size of ICU favorably
affecting outcome [74]. A more recent study of 10 000 ICU patients treated in either a neuro or general
ICU confirmed lower in-hospital mortality of ICH patients treated in the specialized
neurological ICU [75]. The effects were also similar for less acute ICH patients treated in a stroke unit.
A meta-analysis that assessed 13 randomized studies likewise evidenced the cited noticeable
benefits [76]. The main reasons for this association are presumably the expertise of the treatment
team and the dedicated monitoring (clinical, multimodal, and/or invasive) to enable
early detection of threatening secondary complications and a swift response [77]. Furthermore, such specialized neuro intensive care represents a high logistical,
operational, and personnel expense that these specialized centers can carry. There
is hardly any reliable data available explicitly for OAC-ICH patients on the treatment
aspects described in the following. The attempt was therefore made to place the treatment
procedures in the context of the specific characteristics of OAC-ICH and derive a
possible relevance for OAC-ICH patients.
Hematoma evacuation (craniectomy, minimally invasive procedure)
The STICH 1 study was the first major randomized study that investigated hematoma
evacuation surgery in over 1 000 patients with supratentorial ICH. It compared early
hematoma evacuation (diagnosis within 72 h after onset of symptoms) with conservative
treatment. The surgical approach appeared to have a small advantage for patients with
superficial, atypical ICH [78], which was confirmed in meta-analyses of existing RCTs on surgical treatment after
ICH. The STICH 2 study followed, which investigated a neurosurgical approach in patients
with lobar ICH (volume between 10–100 ml) and no intraventricular hemorrhage, located
near the cortex (<1 cm), and accessible for early surgical intervention [79]. A total of 601 patients were randomized and of those surgically treated nearly
all patients (98%) underwent an open craniotomy with hematoma evacuation. There were
no relevant differences with respect to the functional endpoint of the study between
the compared procedures in the intention-to-treat analysis (OR 0.86 (0.62–1.20); p=0.36).
The validity of the study is undermined by the high number of patients (21%) in the
conservative treatment arm who nonetheless were later treated surgically because their
clinical condition worsened but who, for the purposes of the primary endpoint analysis,
were categorized in the conservative-treatment group. Therefore the slight advantage
of surgery – at least for mortality at 6 months – may actually be greater. Minimally
invasive strategies (catheter-based or endoscopic) are being increasingly studied
in light of the sobering results of open surgical procedures. Various meta-analyses
based on predominantly smaller studies suggest, at least for the minimally invasive
approach, advantages in terms of reduced mortality and morbidity compared to other
surgical as well as conservative procedures. The MISTIE II study was a larger randomized
study that investigated, in 118 patients with a supratentorial ICH, a combined approach
of a minimally invasive catheter application and hematoma lysis with rt-PA compared
to conservative treatment. Ultimately the intervention significantly reduced the size
of the hematoma and edema without influencing the functional endpoints [80]
[81]. The follow-up study (MISTIE III) is currently recruiting and is designed to investigate
the efficacy and safety of the procedure adequately (planned inclusion of 500 patients,
until end of 2018) (NCT01827046). Other technical innovations using various endoscopic
systems (e. g., the INVEST study) are currently under investigation. Another albeit
more invasive approach – derived from operative RCTs for malignant middle cerebral
artery infarction – is decompressive hemicraniectomy in patients with basal ganglia
ICH (SWITCH study), which randomly compares it to maximally conservative treatment
(NCT 02258919),
It is somewhat difficult to derive aspects relevant to OAC-ICH from the surgical approach,
however subjective reports indicate that an OAC-ICH may be easier to evacuate because
of the altered coagulation, but data to support this view is lacking. In general,
OAC-ICH is justifiably excluded from surgical trials because altered hemostasis could
theoretically persist in spite of systemic antagonization in the hematoma cavity.
Hemicraniectomy also harbors possible increased risks because the tamponade effect
from cranial bone is removed, and the hematoma encounters less resistance to stopping,
prolonged such as in OAC-ICH.
External ventricle drainage, intraventricular fibrinolysis and lumbar drainage
Intraventricular hemorrhage (IVH) is a known predictor of poor outcome and complicates
the treatment of ICH in approximately 50% of patients. IVH is an immediate, life-threatening
complication that due to the obstruction of the ventricular system – especially the
third and fourth ventricles – can cause an acute hydrocephalus ultimately leading
to herniation [82]. The method of choice for treating the acute rise in intracranial pressure and preventing
herniation is placement of an external ventricular drain (EVD). In the ongoing course
of treatment, procedures such as intraventricular lysis, endoscopic techniques, and
overlapping lumbar drainage offer options to clear intraventricular blood more quickly,
and correlated positively with clinical endpoints in various observational and prospective
pilot studies [83]
[84]
[85]. According to the latest data, intraventricular lysis via rt-PA or urokinase via
EVD is injected into the ventricle system but only after CT has confirmed the size
of the hematoma is stable. This is performed via one or two EVDs with e. g., 1 mg
rt-PA, every 8–12 h until the third and fourth ventricle are clear of blood and communication
between the ventricular and subarachnoid cerebral spinal fluid space is re-established
[46]. This approach was investigated on a large scale for the first time in the CLEAR-IVH
study, starting in 2003. The promising results led to the CLEAR III study, which is
complete but as yet unpublished. Although the results with respect to the primary
endpoint (improved functional status at 6 months) are negative, there is a significant
association with an improved outcome especially in patients with pronounced IVH (IVH
volume>20 ml) (OR: 1.84, p=0.046) at an existing effect size of just under 10%. But
the treatment was associated with a 10% reduction in mortality as a secondary endpoint
(data presented at ISC 2016). Another promising approach is overlapping lumbar drainage.
Theoretically, it should re-establish the physiological circulation of CSF as quickly
as possible and remove intraventricular and subarachnoid blood from the intracranial
compartment. It is hoped that it will prevent exacerbation from blood and its breakdown
products – the strong inflammation mediators. Note that lumbar drainage is a simple
bedside procedure that can be performed during the subacute course. Before placing
the lumbar drain, however, communication between the internal and external CSF system
must be confirmed as re-established, otherwise herniation could theoretically occur.
Previous pilot and observational studies showed that the combination of intraventricular
fibrinolysis and lumbar drainage might be associated with reduced permanent shunt
dependency and an improved outcome [84]
[85]. A smaller, very recent randomized study, including a meta-analysis based on individual
patient data, confirmed in just under 100 patients the safety of this procedure and
its efficacy in avoiding permanent shunts [86]. Endoscopic aspiration of the intraventricular blood represents another approach,
with various techniques already having been described. A small randomized study (n=48)
likewise resulted in a significant reduction in shunt rate [87].
Although the studies cited largely excluded OAC-ICH patients, there are several interesting
implications considering the characteristics of an ICH while under anticoagulation
treatment. As already mentioned, OAC-ICH is associated with a more frequent and greater
extent of IVH. Pathophysiological considerations suggest that IVF with or without
lumbar drainage is not only transferable but could also be more relevant than in primary
ICH because more than half of patients are affected. Furthermore, CLEAR III demonstrated
a positive effect on functional outcome particularly in cases of pronounced ventricular
intrusion, which is much more frequent in OAC-ICH. Note, however, that these considerations
are merely theoretical and there is no evidence to date regarding safety in OAC-ICHs.
Treatment of perihemorrhagic edema
After ICH, perihemorrhagic edema frequently develops that is associated with premature
neurological deterioration and is therefore another negative prognostic parameter
[88]
[89]. The temporal course can be divided into two phases – acute (0–24 h) and late phase
(10–14 days) with maximum edema [90]
[91]. In the acute phase, extravasation of pro-osmotic substances from the blood clot
(proteins, electrolytes) occurs, which can cause premature vasogenic edema [92]. Over time (the next several hours to days), the activation of the coagulation cascade
begins increased thrombin production with an osmotic effect as well as the release
of inflammation mediators through the breakdown of erythrocytes and hemoglobin. This
might be called a mixed vasogenic and cytotoxic edema [91]
[92]. The underlying mechanism of damage is the volume effect of the edema, which can
lead to intracranial hypertension with consecutive cerebral hypoperfusion (local to
global) and secondary brain damage [92]
[93]. A wide variety of substances (hypertonic sodium chloride, mannitol, steroids, chelating
agents) and interventions (hypothermia, decompressive craniectomy) are used to treat
perihemorrhagic edema, but to date there is no valid evidence for definitively recommending
their use [1]
[12]. A current subanalysis of the INTERACT 2 data identified associations with an improved
outcome for mannitol, at least for larger bleeds (>15 ml) [94]. Promising data has emerged from cohort and pilot studies for hypertonic sodium
chloride infusions, among others, deferoxamine (recently published), and mild, prolonged
hypothermia [88]
[95]
[96]. A current review identified 18 studies on the influence of hypothermia on edema
after ICH. Treatment using hypothermia was significantly associated with reduced edema
development and advantages for clinical endpoints. Results from randomized trials
are currently unknown (ISRCTN28699995; NCT01607151). Another subanalysis of the INTERACT
2 data examined temperature regulation and edema development and established a linear
relationship between edema and ambient temperature, i. e., a higher ambient temperature
increased the volume of perihemorrhagic edema [97]. The effect of a decompressive craniectomy was also investigated and did show progressive
and prolonged edema after surgery, although the clinical outcome for those patients
appeared better [98].
For OAC-ICHs in those receiving vitamin K antagonists, experimental data suggest a
possible reduction in edema because thrombin production appears to be less pronounced,
although there are very few clinical trials. Hence no OAC-ICH-specific treatment approach
can be inferred, but early initiation of hypothermia should possibly be avoided because
it can alter coagulation. This stands in contrast to study results in primary ICH
patients that showed hypothermia to positively affect perihemorrhagic edema only when
initiated early (<72 h after onset of symptoms) [96].
Thrombosis and thromboembolism prophylaxis
Compared to ischemic stroke patients, ICH patients suffer much greater functional
impairment, which is associated with a higher degree of immobilization and hence a
greater risk of thrombosis. Early mobilization of stroke patients is therefore viewed
as the most effective way to prevent deep vein thrombosis (DVT) and pulmonary emboli
(PE), but ICH patients can be adequately mobilized only to a limited extent. To date,
only few studies have investigated early thrombosis prophylaxis in ICH patients. A
related meta-analysis indicated that prophylaxis with heparinoids (unfractionated,
low-molecular-weight) may be associated with an increased risk of symptomatic intracerebral
hemorrhage (8.0% versus 4.0%; RR, 1.42 (95% CI: 0.57–3.53; p=0.45), although it does
provide significant protection against pulmonary emboli (1.7% versus 2.9%; RR 0.37
(95% CI: 0.17–0.80); p=0.01) [99]. Thrombosis prophylaxis was not demonstrated to have an effect on mortality. Another
subanalysis of the INTERACT trial population looked at the impact of administering
prophylactic heparin; a propensity-score-matched analysis indicated a significantly
higher rate of disability in heparin-treated patients, although it is unclear whether
the statistically rigorous adjustment procedure adequately corrected the indication
bias [100]. For stroke patients in general, the prospective CLOTS trials (Clots in Legs Or
sTockings after Stroke), which investigated the effectiveness and safety of intermittent,
pneumatic compression, produced the best evidence on the topic of thrombosis prophylaxis
and reported a prevalence of symptomatic deep vein thromboses of less than 5% and
lung emboli of less than 2% [101]. These trial data did not support the use of compression stockings in stroke patients
due to undesirable complications (skin necrosis, ulcers) [101]. The results of the subsequent CLOTS 3 trial showed this intervention to have a
significantly lower risk of deep vein thromboses and possibly higher survival rate
in ICH patients, although skin lesions were more frequent [102].
Compared to general stroke patients, OAC-ICH patients per se have a higher risk of
thromboembolic complications. These patients are therefore in a special risk group
in which the increased risk of hemorrhage must be weighed against the risk of thromboembolism
and the treatment decision (early anticoagulation) considered on an individual basis.
Based on the current state of the data, in general the best-possible, non-drug prophylactic
treatment should be pursued because there is no valid evidence that early anticoagulation
prevents a deep vein thrombosis or systemic thromboembolism in ICH patients. In particular,
patients with mechanical heart valves are another subgroup at greater risk of thromboembolism.
Safety considerations should therefore prevail in treating these patients – and if
justifiable – early anticoagulation be avoided. Older data report a manageable risk
of ischemia of less than 3% within the first 30 days after discontinuing OAK.
Practical Summary
-
OAC-ICH is the most serious form of hemorrhagic stroke and its incidence is expected
to grow.
-
One-year mortality is over 50% and fewer than 30% of patients recover functional independence
(modified Rankin scale 0–3).
-
The main treatment goal in the acute phase should be minimizing hematoma growth.
-
In all cases of OAC-ICH, immediate, intensified measures to lower blood pressure should
be taken (target systolic blood pressure 140 mmHg).
-
In cases of VKA-ICH, immediate antagonization (at least within 4 h) to INR values
less than 1.3 or 1.2 using PCC and vitamin K should be pursued.
-
For dabigatran-associated ICH, 5 mg of idarucizumab should be administered immediately
for antagonization.
-
There is no evidence in the case of factor Xa inhibitor-associated ICH, and antagonization
using PCC or FEIBA should be considered as a substitute.
-
In the sub-acute phase (as of day 2), specific ICH therapies are employed, but an
individual risk-benefit analysis is of utmost importance with respect to increased
risk of hemorrhage and thromboembolism (hematoma evacuation, edema therapy, thrombosis
prophylaxis).
-
Intraventricular fibrinolysis with overlapping lumbar drainage, if needed, could theoretically
be clinically relevant because of the increased and greater extent of IVH that is
characteristic in OAC-ICHs.
